US2013259895A1PendingUtilityA1

Nf-kb inhibitor

Assignee: MARUHACHI MURAMATSU INCPriority: Apr 2, 2012Filed: Mar 22, 2013Published: Oct 3, 2013
Est. expiryApr 2, 2032(~5.7 yrs left)· nominal 20-yr term from priority
A61P 9/00A61P 43/00A61P 37/08A61P 31/04A61P 27/02A61P 31/12A61P 35/00A61P 31/20A61P 29/00A61P 31/00A61P 31/14A61P 19/06A61P 1/00A61P 17/06A61P 13/12A61P 1/04A61P 25/00A61P 1/18A61P 11/08A61P 1/16A61P 11/02A61P 11/06A61P 17/00A61P 11/00A61P 19/02A61K 36/03
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An NF-κB inhibitor which can be easily obtained and consumed in daily dietary life and can inhibit transcription activation by NF-κB is provided. When osteoblasts in which NF-κB is activated by TNF-α is cultured in a medium containing Sargassum horneri or a processed product thereof, for example, a Sargassum horneri water extract of molecular weight up to 3,000, transcription activation by NF-κB can be inhibited. In addition, when osteoclast precursor cells in which NF-κB is activated by RANKL is cultured in a medium containing Sargassum horneri or a processed product, for example, a Sargassum horneri water extract thereof of molecular weight up to 3,000, transcription activation by NF-κB can be inhibited.

Claims

exact text as granted — not AI-modified
1 . An NF-κB inhibitor comprising  Sargassum horneri  or a processed product thereof as an active ingredient. 
     
     
         2 . The NF-κB inhibitor according to  claim 1 , wherein the processed product of  Sargassum horneri  is an extract of  Sargassum horneri.    
     
     
         3 . The NF-κB inhibitor according to  claim 2 , wherein the extract of  Sargassum horneri  is a water extract of  Sargassum horneri.    
     
     
         4 . The NF-κB inhibitor according to  claim 3 , wherein the water extract of  Sargassum horneri  is a  Sargassum horneri  water extract having a molecular weight of 3,000 or less. 
     
     
         5 . A composition for inhibiting transcription activation by NF-κB, comprising the NF-κB inhibitor according to  claim 1 . 
     
     
         6 . A composition for inhibiting transcription activation by NF-κB, comprising the NF-κB inhibitor according to  claim 2 . 
     
     
         7 . A composition for inhibiting transcription activation by NF-κB, comprising the NF-κB inhibitor according to  claim 3 . 
     
     
         8 . A composition for inhibiting transcription activation by NF-κB, comprising the NF-κB inhibitor according to  claim 4 .

Join the waitlist — get patent alerts

Track US2013259895A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.